Document Detail


Clinical Trial of the Intratumoral Administration of Labeled DC Combined With Systemic Chemotherapy for Esophageal Cancer.
MedLine Citation:
PMID:  22735809     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Esophageal cancer is a highly aggressive disease, and improved modalities for its treatment are needed. We performed chemoimmunotherapy involving the intratumoral administration of In-labeled dendritic cells (DC) in combination with preoperative chemotherapy in 5 esophageal cancer patients. Mature DC were generated and traced by scintigraphy after their administration. No adverse events that were directly related to the intratumoral DC administration were observed. Delayed-type hypersensitivity skin tests against keyhole limpet hemocyanin, which was added to the culture medium, detected a positive response in 3 patients, and keyhole limpet hemocyanin antibody production was observed in 4 patients, suggesting that intratumorally administered DC migrate to the lymph nodes, where they function as antigen-presenting cells. However, scintigraphic images obtained after the DC administration demonstrated that the DC remained at the esophageal tumor injection sites in all cases, and no DC accumulation was observed elsewhere. The accumulation of CD83 cells in the primary tumor was also observed in 2 out of 4 patients in an immunohistochemical analysis using surgically resected specimens. Although the induction of tumor-specific immune responses during chemoimmunotherapy was also analyzed in enzyme-linked immunosorbent assay against 28 tumor antigens, none of the antibodies against the antigens displayed enhanced titers. No changes of NY-ESO-1-specific cellular immune response was observed in a patient who displayed NY-ESO-1 antibody production before the DC administration. These results suggest that the intratumoral administration of In-labeled mature DC during chemotherapy does not lead to detectable DC migration from the primary tumor to the draining lymph nodes, and therefore, might not achieve an optimal clinical response.
Authors:
Shinichi Fujiwara; Hisashi Wada; Hiroshi Miyata; Junji Kawada; Ryohei Kawabata; Hiroyoshi Nishikawa; Sacha Gnjatic; Christine Sedrak; Eiichi Sato; Yurika Nakamura; Mitsuru Sakakibara; Tatsuya Kanto; Eku Shimosegawa; Jun Hatazawa; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Shuji Takiguchi; Eiichi Nakayama; Masaki Mori; Yuichiro Doki
Related Documents :
22740849 - Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microrna...
22865089 - Automatic laser scanning ablation system for high-precision treatment of brain tumors.
11025469 - Clinical use of topoisomerase i inhibitors in anticancer treatment.
22740829 - Decreased vision and junctional scotoma from pituicytoma.
22851709 - An nkp30-based chimeric antigen receptor promotes t cell effector functions and antitum...
22483639 - Renal cell neoplasms contain shared tumor type-specific copy number variations.
14710349 - Caloric restriction and insulin-like growth factors in aging and cancer.
22740849 - Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microrna...
16537179 - Cell cycle control related proteins (p53, p21, and rb) and transforming growth factor b...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of immunotherapy (Hagerstown, Md. : 1997)     Volume:  35     ISSN:  1537-4513     ISO Abbreviation:  J. Immunother.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9706083     Medline TA:  J Immunother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  513-21     Citation Subset:  IM    
Affiliation:
Departments of *Gastroenterological Surgery ∥Gastroenterology and Hepatology ¶Nuclear Medicine, Graduate School of Medicine †Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka §Department of Pathology, Tokyo Medical University, Tokyo #Faculty of Health and Welfare, Kawasaki University of Medical Welfare, Kurashiki, Japan ‡New York Branch at the Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, New York, NY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction a...
Next Document:  Platelet-derived growth factor (PDGF) induces pulmonary vascular remodeling through 15-LO/15-HETE pa...